Richland WA, Jun. 24, 2020 (GLOBE NEWSWIRE) --

Vivos Inc. (OTCQB: RDGL), Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel™ for human therapy. Animal testing at the University of Missouri was completed in 2019. Since then we have been focusing on completing the Radiogel™ Quality Management System (“QMS”). Our QMS validates that the pedigree of all future testing complies with the strict FDA guidelines. This week we initiated the biocompatibility testing contract as part of the previously defined pre-clinical testing. We are targeting to present our interim results to the FDA in a pre-submission meeting this year. This will set the stage for submittal of the Investigational Device Exemption (IDE). FDA approval of the IDE is required to begin clinical trials in humans. We believe that approval of the IDE will significantly enhance the potential partnering and licensing opportunities for Radiogel™.

 >> Read Full Release